{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:56:56Z","timestamp":1785884216829,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R006458\/1"],"award-info":[{"award-number":["MR\/R006458\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mitochondrial disease is a heterogenous group of rare, complex neurometabolic disorders. Despite their individual rarity, collectively mitochondrial diseases represent the most common cause of inherited metabolic disorders in the UK; they affect 1 in every 4300 individuals, up to 15,000 adults (and a similar number of children) in the UK. Mitochondrial disease manifests multisystem and isolated organ involvement, commonly affecting those tissues with high energy demands, such as skeletal muscle. Myopathy manifesting as fatigue, muscle weakness and exercise intolerance is common and debilitating in patients with mitochondrial disease. Currently, there are no effective licensed treatments and consequently, there is an urgent clinical need to find an effective drug therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To investigate the efficacy of 12-week treatment with acipimox on the adenosine triphosphate (ATP) content of skeletal muscle in patients with mitochondrial disease and myopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>AIMM is a single-centre, double blind, placebo-controlled, adaptive designed trial, evaluating the efficacy of 12 weeks\u2019 administration of acipimox on skeletal muscle ATP content in patients with mitochondrial myopathy. Eligible patients will receive the trial investigational medicinal product (IMP), either acipimox or matched placebo. Participants will also be prescribed low dose aspirin as a non-investigational medical product (nIMP) in order to protect the blinding of the treatment assignment.<\/jats:p>\n                <jats:p>Eighty to 120 participants will be recruited as required, with an interim analysis for sample size re-estimation and futility assessment being undertaken once the primary outcome for 50 participants has been obtained. Randomisation will be on a 1:1 basis, stratified by Fatigue Impact Scale (FIS) (dichotomised as &lt; 40, \u2265 40). Participants will take part in the trial for up to 20 weeks, from screening visits through to follow-up at 16 weeks post randomisation.<\/jats:p>\n                <jats:p>The primary outcome of change in ATP content in skeletal muscle and secondary outcomes relating to quality of life, perceived fatigue, disease burden, limb function, balance and walking, skeletal muscle analysis and symptom-limited cardiopulmonary fitness (optional) will be assessed between baseline and 12 weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The AIMM trial will investigate the effect of acipimox on modulating muscle ATP content and whether it can be repurposed as a new treatment for mitochondrial disease with myopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-002721-29\">EudraCT2018-002721-29<\/jats:ext-link>. Registered on 24 December 2018,<\/jats:p>\n                <jats:p>ISRCTN 12895613. Registered on 03 January 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/search?q=aimm\">https:\/\/www.isrctn.com\/search?q=aimm<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06544-x","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T10:13:38Z","timestamp":1663668818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy"],"prefix":"10.1186","volume":"23","author":[{"name":"The AIMM Trial Group:","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abouhajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Alcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theophile","family":"Bigirumurame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Del Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Faitg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Falkous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e1inne S.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Lakey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesther","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renae J.","family":"Stefanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-7105","authenticated-orcid":false,"given":"Naomi J.P.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"6544_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.mam.2004.03.001","volume":"25","author":"MR Duchen","year":"2004","unstructured":"Duchen MR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Asp Med. 2004;25:365\u2013451.","journal-title":"Mol Asp Med"},{"issue":"5","key":"6544_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ana.24362","volume":"M77","author":"GS Gorman","year":"2015","unstructured":"Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;M77(5):753\u20139.","journal-title":"Ann Neurol"},{"key":"6544_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.80","volume":"2","author":"GS Gorman","year":"2016","unstructured":"Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:1\u201322.","journal-title":"Nat Rev Dis Primers"},{"key":"6544_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40291-020-00510-6","volume":"25","author":"RJ Tinker","year":"2021","unstructured":"Tinker RJ, Lim AZ, Stefanetti RJ, McFarland R. Current and emerging clinical treatment in mitochondrial disease. Mol Diagn Ther. 2021;25:181\u2013206.","journal-title":"Mol Diagn Ther"},{"key":"6544_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cell.2020.02.051","volume":"181","author":"OM Russell","year":"2020","unstructured":"Russell OM, Gorman GS, Lightowlers RN, Turnbull DM. Mitochondrial diseases: hope for the future. Cell. 2020;181:168\u201388.","journal-title":"Cell."},{"key":"6544_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ymgme.2016.09.002","volume":"119","author":"KM Camp","year":"2016","unstructured":"Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, et al. Nutritional interventions in primary mitochondrial disorders: developing an evidence base. Mol Genet Metab. 2016;119:187\u2013206.","journal-title":"Mol Genet Metab"},{"key":"6544_CR7","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1093\/brain\/awl282","volume":"129","author":"T Taivassalo","year":"2007","unstructured":"Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain. 2007;129:3391\u2013401.","journal-title":"Brain."},{"key":"6544_CR8","doi-asserted-by":"crossref","unstructured":"Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2012;(4):CD004426.","DOI":"10.1002\/14651858.CD004426.pub3"},{"key":"6544_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MOL.0b013e328328d0a4","volume":"20","author":"C Canto","year":"2009","unstructured":"Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20:98\u2013105.","journal-title":"Curr Opin Lipidol"},{"key":"6544_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1083\/jcb.201207019","volume":"199","author":"RH Houtkooper","year":"2012","unstructured":"Houtkooper RH, Auwerx J. Exploring the therapeutic space around NAD(+). J Cell Biol. 2012;199:205\u20139.","journal-title":"J Cell Biol"},{"key":"6544_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/030006058901700411","volume":"17","author":"M Lavezzari","year":"1989","unstructured":"Lavezzari M, Milanesi G, Oggioni E, Pamparana F. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia. Int J Med Res. 1989;17:373\u201380.","journal-title":"Int J Med Res"},{"key":"6544_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2337\/db14-0667","volume":"64","author":"T van de Weijer","year":"2015","unstructured":"van de Weijer T, Phielix E, Bilet L, Williams EG, Ropelle ER, Bierwagen A, et al. Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes. 2015;64:1193\u2013201.","journal-title":"Diabetes"},{"key":"6544_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yebeh.2013.11.008","volume":"31","author":"D Victorson","year":"2014","unstructured":"Victorson D, Cavazos JE, Holmes GL, Reder AT, Wojna V, Nowinski C, et al. Validity of the neurology quality of life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behav. 2014;31:77\u201384.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"6544_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2012.12.012","volume":"23","author":"JL Elson","year":"2013","unstructured":"Elson JL, Cadogan M, Apabhai S, Whittaker RG, Phillips A, Trennell MI, et al. Initial development and validation of a mitochondrial disease quality of life scale. Neuromuscul Disord. 2013;23(4):324\u20139.","journal-title":"Neuromuscul Disord"},{"key":"6544_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1017\/S0033291700009934","volume":"18","author":"HM McCormack","year":"1988","unstructured":"McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007\u201319.","journal-title":"Psychol Med"},{"issue":"2","key":"6544_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/occmed\/kqp180","volume":"60","author":"J Frith","year":"2010","unstructured":"Frith J, Newton J. Fatigue impact scale. Occup Med. 2010;60(2):159.","journal-title":"Occup Med"},{"issue":"Suppl 1","key":"6544_CR17","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79\u201383.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6544_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121\u20133.","journal-title":"Arch Neurol"},{"issue":"4","key":"6544_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/bjsm.22.4.153","volume":"22","author":"RG Eston","year":"1988","unstructured":"Eston RG, Williams JG. Reliability of ratings of perceived effort regulation of exercise intensity. Br J Sports Med. 1988;22(4):153\u20135.","journal-title":"Br J Sports Med"},{"issue":"12","key":"6544_CR20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1212\/01.wnl.0000219759.72195.41","volume":"66","author":"AM Schaefer","year":"2006","unstructured":"Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology. 2006;66(12):1932\u20134.","journal-title":"Neurology."},{"issue":"1","key":"6544_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Statement","year":"2002","unstructured":"Statement ATS. Guidelines for the six minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"6544_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1532-5415.2003.51104.x","volume":"51","author":"S Studenski","year":"2003","unstructured":"Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney E, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51(3):314\u201322.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"6544_CR23","first-page":"225","volume":"61","author":"K Potter","year":"2015","unstructured":"Potter K, Brandfass K. The mini-balance evaluation systems test (mini-BESTest). J Phys. 2015;61(4):225.","journal-title":"J Phys"},{"issue":"2","key":"6544_CR24","first-page":"77","volume":"25","author":"M Kellor","year":"1971","unstructured":"Kellor M, Frost J, Silberberg N, Iversen I, Cummings R. Hand strength and dexterity. Am J Occup Ther. 1971;25(2):77\u201383.","journal-title":"Am J Occup Ther"},{"key":"6544_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1123\/japa.7.2.129","volume":"7","author":"RE Rikli","year":"1999","unstructured":"Rikli RE. Development and validation of a functional fitness test for community-residing older adults. J Aging Phys Act. 1999;7:129\u201361.","journal-title":"J Aging Phys Act"},{"issue":"11","key":"6544_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/mds.21544","volume":"22","author":"A Weyer","year":"2007","unstructured":"Weyer A, Abele M, Schmitz-H\u00fcbsch T, Schoch B, Frings M, Timmann D. Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord. 2007;22(11):1633\u20137.","journal-title":"Mov Disord"},{"issue":"11","key":"6544_CR27","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia, development of a new clinical scale. Neurology. 2006;66(11):1717\u201320.","journal-title":"Neurology."},{"key":"6544_CR28","doi-asserted-by":"crossref","unstructured":"Galna B, Newman J, Jakovljevic DG, et al. Discrete gait characteristics are associated with m.3243A>G and\u00a0m.8344A>G variants of mitochondrial disease and its pathological consequences. J Neurol. 2014;261(1):73\u201382.","DOI":"10.1007\/s00415-013-7129-2"},{"issue":"3","key":"6544_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1023\/A:1015295106602","volume":"11","author":"JD Fisk","year":"2002","unstructured":"Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002;11(3):263\u201372.","journal-title":"Qual Life Res"},{"key":"6544_CR30","first-page":"45","volume-title":"Sample sizes for clinical trials","author":"SA Julious","year":"2010","unstructured":"Julious SA. Sample sizes for clinical trials. New York: Chapman and Hall; 2010. p. 45."},{"issue":"17-18","key":"6544_CR31","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/sim.733","volume":"20","author":"AL Gould","year":"2001","unstructured":"Gould AL. Sample size re-estimation: recent developments and practical considerations. Stat Med. 2001;20(17-18):2625\u201343.","journal-title":"Stat Med"},{"key":"6544_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1745-6215-15-61","volume":"15","author":"B Sully","year":"2014","unstructured":"Sully B, Julious S, Nichol J. An investigation of the impact of futility analysis in publicly funded trials. Trials. 2014;15:61.","journal-title":"Trials"}],"updated-by":[{"DOI":"10.1186\/s13063-022-06814-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06544-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T06:13:55Z","timestamp":1665036835000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6544"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06544-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-022-06814-8","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-022-06814-8","URL":"https:\/\/doi.org\/10.1186\/s13063-022-06814-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Favourable ethical opinion has been granted by the UK Health Research Authority Research Ethics Committee (Northern Ireland: HSC REC B; reference 18\/NI\/0199) and the UK MHRA (reference: 2018-002721-29). Confirmation of capacity and capability is received. The trial is included in the National Institute for Health Research Clinical Research Network (NIHR CRN) portfolio (reference: 40330).Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Not applicable; no identifying personal or clinical participant details or images are included within this protocol paper. No identifiable material will be presented in reports of the trial results. Informed consent materials are attached as .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"789"}}